Epicurious.

TRAIN-2 demonstrated there was no advantage in the (very impressive) pathologic complete response (pCR) rate to neoadjuvant systemic therapy whether or not it included an anthracycline. As a reminder, among over 438 women receiving dual HER2-targeted therapies, the pCR rate was a remarkable 67-68% with or without epirubicin. Three-year follow-up now demonstrates this translates into excellent event-free survival rates of 93-94%. What epirubicin did buy, though, was more clinically significant declines in left ventricular ejection fraction. | van der Voort, JAMA Oncol 2021